- Home
- Publications
- Publication Search
- Publication Details
Title
New Therapeutics Options for Pediatric Neuromuscular Disorders
Authors
Keywords
-
Journal
Frontiers in Pediatrics
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-23
DOI
10.3389/fped.2020.583877
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Golodirsen: First Approval
- (2020) Young-A Heo DRUGS
- Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
- (2020) Erik Landfeldt et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
- (2020) Diane E. Frank et al. NEUROLOGY
- Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
- (2020) Eugenio Mercuri et al. Journal of Comparative Effectiveness Research
- European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
- (2020) Janbernd Kirschner et al. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
- Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
- (2020) James M. Wilson et al. HUMAN GENE THERAPY
- Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future
- (2020) Suzan Boutary et al. Translational Research
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy
- (2020) Jerry R. Mendell et al. JAMA Neurology
- New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
- (2020) Sonia Messina et al. Journal of Clinical Medicine
- Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1
- (2019) Vera Fridman et al. NEUROLOGY
- Newborn screening for SMA in Southern Belgium
- (2019) François BOEMER et al. NEUROMUSCULAR DISORDERS
- X-linked myotubular myopathy
- (2019) Mélanie Annoussamy et al. NEUROLOGY
- Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1
- (2019) Omar Dabbous et al. ADVANCES IN THERAPY
- Impact of age and motor function in a phase 1/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy
- (2019) Linda P. Lowes et al. PEDIATRIC NEUROLOGY
- The congenital myasthenic syndromes
- (2019) An E. Vanhaesebrouck et al. CURRENT OPINION IN NEUROLOGY
- Onasemnogene Abeparvovec: First Global Approval
- (2019) Sheridan M. Hoy DRUGS
- Charcot-Marie-Tooth: From Molecules to Therapy
- (2019) Jonathan Morena et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Progress and challenges of gene therapy for Pompe disease
- (2019) Giuseppe Ronzitti et al. Annals of Translational Medicine
- Long-term outcome and unmet needs in infantile-onset Pompe disease
- (2019) Andreas Hahn et al. Annals of Translational Medicine
- Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164–76. doi:10.1007/s12325-019-00923-8
- (2019) Alfred W. Sandrock et al. ADVANCES IN THERAPY
- Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
- (2019) Eric P. Hoffman et al. NEUROLOGY
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
- (2019) Darryl C. De Vivo et al. NEUROMUSCULAR DISORDERS
- P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy
- (2019) G. Baranello et al. NEUROMUSCULAR DISORDERS
- Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
- (2019) Laurent Servais et al. NEUROMUSCULAR DISORDERS
- Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1
- (2019) Lubov Timchenko INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease
- (2019) Dwight D. Koeberl et al. MOLECULAR GENETICS AND METABOLISM
- Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy
- (2018) Rachael A. Potter et al. HUMAN GENE THERAPY
- Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
- (2018) Craig M McDonald et al. LANCET
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
- (2018) David J Birnkrant et al. LANCET NEUROLOGY
- Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy
- (2018) Alessandra Govoni et al. MOLECULAR NEUROBIOLOGY
- Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy
- (2018) Dongsheng Duan MOLECULAR THERAPY
- Untangling the complexity of limb-girdle muscular dystrophies
- (2018) Teerin Liewluck et al. MUSCLE & NERVE
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
- (2018) Richard S. Finkel et al. NEUROMUSCULAR DISORDERS
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes
- (2018) Eric P. Hoffman et al. STEROIDS
- Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1
- (2018) Marta López-Morató et al. Frontiers in Neurology
- Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial
- (2018) Guillaume Bassez et al. BRAIN
- Pompe Disease: From Basic Science to Therapy
- (2018) Lara Kohler et al. Neurotherapeutics
- A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
- (2018) Stefan Sturm et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease
- (2018) Mo Zhao et al. Neurotherapeutics
- Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy
- (2018) Suzie Buono et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A
- (2017) Michael E. Shy JOURNAL OF CLINICAL INVESTIGATION
- PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
- (2017) Hien Tran Zhao et al. JOURNAL OF CLINICAL INVESTIGATION
- Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Craig M McDonald et al. LANCET
- Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice
- (2017) Eric R. Pozsgai et al. MOLECULAR THERAPY
- Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review
- (2017) Basmah El-Aloul et al. NEUROMUSCULAR DISORDERS
- Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy
- (2017) Janbernd Kirschner et al. NEUROPEDIATRICS
- Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
- (2017) Jerry R. Mendell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
- (2017) Viviana Giannuzzi et al. Orphanet Journal of Rare Diseases
- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
- (2016) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- The importance of genetic diagnosis for Duchenne muscular dystrophy
- (2016) Annemieke Aartsma-Rus et al. JOURNAL OF MEDICAL GENETICS
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
- (2016) Craig Campbell et al. MUSCLE & NERVE
- Progress and challenges in diagnosis of dysferlinopathy
- (2016) Marina Fanin et al. MUSCLE & NERVE
- Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
- (2016) C. McDonald et al. NEUROMUSCULAR DISORDERS
- Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies
- (2015) J Scharner et al. GENE THERAPY
- Charcot–Marie–Tooth diseases: an update and some new proposals for the classification
- (2015) Stéphane Mathis et al. JOURNAL OF MEDICAL GENETICS
- Molecular and clinical features of inherited neuropathies due to PMP22 duplication
- (2015) M.M. Watila et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Myotonic dystrophy
- (2014) Chris Turner et al. CURRENT OPINION IN NEUROLOGY
- Ataluren: First Global Approval
- (2014) Nicola J. Ryan DRUGS
- An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
- (2014) Shahram Attarian et al. Orphanet Journal of Rare Diseases
- PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies
- (2014) Barbara W van Paassen et al. Orphanet Journal of Rare Diseases
- Eteplirsen for the treatment of Duchenne muscular dystrophy
- (2013) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
- (2013) Zarife Sahenk et al. MOLECULAR THERAPY
- The cooperative international neuromuscular research group duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used
- (2013) Craig M. McDonald et al. MUSCLE & NERVE
- A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C
- (2012) Serge Herson et al. BRAIN
- Consensus treatment recommendations for late-onset Pompe disease
- (2011) Edward J. Cupler et al. MUSCLE & NERVE
- Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial
- (2011) Gunnar M. Buyse et al. NEUROMUSCULAR DISORDERS
- Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D
- (2010) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
- (2010) Ans T. van der Ploeg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins
- (2009) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
- (2009) Katharine Bushby et al. LANCET NEUROLOGY
- Diagnostic criteria for late-onset (childhood and adult) pompe disease
- (2009) MUSCLE & NERVE
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
- (2009) Priya S Kishnani et al. PEDIATRIC RESEARCH
- Pompe's disease
- (2008) Ans T van der Ploeg et al. LANCET
- Spinal muscular atrophy
- (2008) Mitchell R Lunn et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started